Utility of Activated Nitriles in the Synthesis of Novel Heterocyclic Compounds with Antitumor Activity

Table 1

In vitro anticancer screening of the synthesized compounds against human breast cancer cell line (MCF-7) at different concentration.

Compd. no.	Compound concentrations (μg/mL)
	1.56 (μg/mL)	3.125 (μg/mL)	6.25 (μg/mL)	12.5 (μg/mL)	25 (μg/mL)	50 (μg/mL)	IC50 (μg/mL)
doxorubicin	30.86	21.18	17.22	11.74	6.55	3.24	0.426
3a	94.28	85.92	73.36	98.63	47.25	14.94	23.4
3b	94.76	89.14	80.92	67.48	54.3	22.38	28.4
4a	95.08	88.93	79.34	67.68	47.92	16.58	23.7
4b	98.48	93.07	87.12	72.35	51.94	27.19	27
6a	97.32	86.46	77.95	48.52	27.04	10.71	12.2
6b	100	97.68	89.73	73.48	51.42	19.17	26.1
11b	84.58	69.75	56.84	23.08	19.32	10.58	7.5
14	100	98.17	91.98	86.3	63.62	29.56	35
15	100	96.54	88.72	73.91	60.58	28.92	33.4
16	91.96	82.55	71.67	50.11	41.36	29.18	12.6
18b	96.98	93.14	76.92	68.45	59.73	31.08	33.5
19a	100	98.42	93.16	90.34	78.19	61.92	50
19b	89.34	81.9	69.79	53.41	38.18	26.87	15.3
21	93.81	88.94	79.22	63.75	16.28	9.64	16.1
22	80.36	69.42	61.87	56.39	41.81	18.26	18

IC50 value: corresponds to the concentration required for 50% inhibition of cell viability.